Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report)'s share price was up 15.6% on Monday . The company traded as high as $11.94 and last traded at $11.57. Approximately 54,091 shares were traded during trading, a decline of 77% from the average daily volume of 240,327 shares. The stock had previously closed at $10.01.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on the stock. Leerink Partnrs raised shares of Maze Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 25th. TD Cowen raised Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. Guggenheim reissued a "buy" rating and issued a $19.00 target price on shares of Maze Therapeutics in a report on Wednesday, April 2nd. Leerink Partners started coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They set an "outperform" rating and a $28.00 price target for the company. Finally, JPMorgan Chase & Co. began coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They issued an "overweight" rating and a $30.00 price objective on the stock. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $25.67.
View Our Latest Research Report on MAZE
Maze Therapeutics Price Performance
The firm has a 50 day simple moving average of $9.67.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.39).
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the company. General Catalyst Group Management LLC purchased a new stake in Maze Therapeutics in the 1st quarter worth $11,405,000. Bessemer Group Inc. bought a new position in shares of Maze Therapeutics in the first quarter worth about $5,305,000. Bank of New York Mellon Corp purchased a new stake in shares of Maze Therapeutics during the first quarter worth about $190,000. New York State Common Retirement Fund bought a new stake in Maze Therapeutics during the 1st quarter valued at approximately $25,000. Finally, Alphabet Inc. purchased a new position in Maze Therapeutics in the 1st quarter worth approximately $26,561,000.
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Featured Stories
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
